MacroGenics reported $204.94M in Current Assets for its fiscal quarter ending in June of 2025.


Current Assets Change Date
AbbVie USD 27.68B 2.09B Mar/2025
Amgen USD 26.73B 195M Jun/2025
AstraZeneca USD 28.94B 2.8B Jun/2025
Biogen USD 7.97B 341.7M Jun/2025
Bristol-Myers Squibb USD 33.22B 2.44B Jun/2025
Daiichi Sankyo JPY 1.85T 62.54B Jun/2025
Eli Lilly USD 49.85B 8.59B Jun/2025
Genmab DKK 3.91B 127M Jun/2025
Geron USD 505.6M 9.83M Jun/2025
Gilead Sciences USD 14.72B 2.18B Jun/2025
J&J USD 71.55B 15.66B Mar/2025
MacroGenics USD 204.94M 12.55M Jun/2025
Merck USD 37.07B 1.56B Jun/2025
Pfizer USD 43.7B 2.16B Jun/2025
Regeneron Pharmaceuticals USD 16.86B 712.2M Jun/2025
Roche Holding CHF 40.04B 6.41B Dec/2024
Xencor USD 513.15M 8.12M Jun/2025